Neuroleptic malignant syndrome

Arquivos de Neuro-Psiquiatria

Mariana Moscovich²  Felipe T.m. Nóvak¹  Artur F. Fernandes¹  Tatiana Bruch²  Tabita Tomelin²  Edison M. Nóvak¹  Renato P. Munhoz²  Hélio A.g. Teive¹ 

[1] ,Pontifical Catholic University of Paraná Department of Neurology Curitiba PR ,Brazil

关键词: atypical antipsychotics;    typical antipsychotics;    neuroleptic malignant syndrome;    neurolépticos atípicos;    neurolépticos típicos;    síndrome neuroléptica maligna;   

DOI  :  10.1590/S0004-282X2011000600005

来源: SciELO

【 摘 要 】

Neuroleptic malignant syndrome (NMS) is a potentially fatal adverse event associated with the use of antipsychotics (AP). The objective of this study was to investigate the profile of cases of NMS and to compare our findings with those published in similar settings. A series of 18 consecutive patients with an established diagnosis of NMS was analyzed, gathering data on demography, symptoms and signs. Two thirds of all cases involved woman with a past medical history of psychiatric disorder receiving relatively high doses of AP. The signs and symptoms of NMS episodes were similar to those reported in other series and only one case had a fatal outcome, the remaining presenting complete recovery. As expected, more than two thirds of our cases were using classic AP (68%), however the clinical profile of these in comparison with those taking newer agent was similar. Newer AP also carry the potential for NMS.

【 授权许可】

CC BY   
 All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License